Compare GXO Logistics Inc (GXO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GXO Logistics Inc vs BIO-TECHNE Corp — how do they compare? GXO Logistics Inc trades at $46.53 (market cap $5.27B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 2.2× GXO Logistics Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and BIO-TECHNE Corp for 63 Days on average.
| GXO | TECH | |
|---|---|---|
Market Cap | $5.27B | $11.37B |
Volume | 978,056 | 3,153,511 |
Sector | Industrials | Health |
52-Week High | $65.59 | $72.61 |
52-Week Low | $44.17 | $43.31 |
Typical Hold Time | 28 Days | 63 Days |
Enterprise Value | $10.62B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GXO Logistics trades at $45.99, down 0.88% on the day, with a neutral technical signal. The company reported revenue of $13.18B in 2025, with net income of $32M, and has beaten EPS estimates for the last three quarters. Recent news highlights strategic partnerships, such as the 10-year logistics deal with Columbia Sportswear in Europe (GlobeNewsWire, 2026-09-29) and leadership expansion in aerospace & defense. Analyst consensus is strongly bullish with a $66.67 price target.
The outlook for GXO is positive, driven by strong analyst support and operational growth, including a projected net cash flow increase to $566M in 2026. Key risks include thin profit margins and competitive pressures in the logistics sector. The stock presents an opportunity based on valuation metrics like a low P/S ratio of 0.39, but investors should monitor margin improvements and execution of new business initiatives.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GXO Logistics Inc
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
